Related Experiment Video
Updated: Jun 2, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate
Elena Miñones-Moyano1, Sílvia Porta, Georgia Escaramís
1Genetic Causes of Disease Group, Genes and Disease Program, Centre for Genomic Regulation, Barcelona, Catalonia, Spain.
Abstract:
MicroRNAs (miRNAs) are post-transcriptional gene expression regulators, playing key roles in neuronal development, plasticity and disease. Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the presence of protein inclusions or Lewy bodies and a progressive loss of dopaminergic neurons in the midbrain. Here, we have evaluated miRNA expression deregulation in PD brain samples. MiRNA expression profiling revealed decreased expression of miR-34b and miR-34c in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease, including the amygdala, frontal cortex, substantia nigra and cerebellum. Furthermore, misregulation of miR-34b/c was detected in pre-motor stages (stages 1-3) of the disease, and thus in cases that did not receive any PD-related treatment during life. Depletion of miR-34b or miR-34c in differentiated SH-SY5Y dopaminergic neuronal cells resulted in a moderate reduction in cell viability that was accompanied by altered mitochondrial function and dynamics, oxidative stress and reduction in total cellular adenosin triphosphate content. MiR-34b/c downregulation was coupled to a decrease in the expression of DJ1 and Parkin, two proteins associated to familial forms of PD that also have a role in idiopathic cases. Accordingly, DJ1 and Parkin expression was reduced in PD brain samples displaying strong miR-34b/c downregulation. We propose that early deregulation of miR-34b/c in PD triggers downstream transcriptome alterations underlying mitochondrial dysfunction and oxidative stress, which ultimately compromise cell viability. A better understanding of the cellular pathways controlling and/or controlled by miR-34b/c should allow identification of targets for development of therapeutic approaches.
Insights
Early downregulation of microRNAs (miRNAs) miR-34b and miR-34c is linked to Parkinson's disease (PD) pathology, affecting neuronal viability and mitochondrial function. This suggests potential therapeutic targets for PD.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) regulate gene expression and are crucial for neuronal function.
- Parkinson's disease (PD) involves dopaminergic neuron loss and protein aggregates.
- miRNA deregulation is implicated in neurodegenerative disorders.
Purpose of the Study:
- To investigate miRNA expression changes in Parkinson's disease brain samples.
- To explore the functional consequences of specific miRNA dysregulation in dopaminergic cells.
- To identify potential molecular links between miRNA changes and PD pathogenesis.
Main Methods:
- miRNA expression profiling in PD brain tissues across different Braak stages.
- In vitro studies using differentiated SH-SY5Y dopaminergic neuronal cells with miR-34b/c depletion.
- Analysis of cell viability, mitochondrial function, oxidative stress, and ATP content.
- Western blot analysis of DJ1 and Parkin protein levels.
Main Results:
- Decreased expression of miR-34b and miR-34c was observed in PD brains at both pre-motor and clinical stages.
- Depletion of miR-34b/c in dopaminergic cells reduced viability, impaired mitochondrial function, increased oxidative stress, and lowered ATP levels.
- Downregulation of miR-34b/c correlated with reduced expression of DJ1 and Parkin proteins in PD samples.
Conclusions:
- Early miR-34b/c downregulation in Parkinson's disease contributes to mitochondrial dysfunction and oxidative stress.
- This miRNA dysregulation impacts neuronal viability and is linked to reduced DJ1 and Parkin expression.
- Targeting miR-34b/c pathways may offer novel therapeutic strategies for Parkinson's disease.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
MicroRNAs
MicroRNAs
Neural Regulation
Parkinson Disease l: Introduction
